Rationale: Ferroptosis is a regulated process of cell death caused by iron-dependent accumulation of lipid hydroperoxides (LPO). It is sensitive to epithelial-to-mesenchymal transition (EMT) cells, a well-known therapy-resistant state of cancer. Previous studies on nanomaterials did not investigate the immense value of ferroptosis therapy (FT) in epithelial cell carcinoma during EMT. Herein, we describe an EMT-specific nanodevice for a comprehensive FT strategy involving LPO burst.Methods: Mitochondrial membrane anchored oxidation/reduction response and Fenton-Reaction-Accelerable magnetic nanophotosensitizer complex self-assemblies loading sorafenib (CSO-SS-Cy7-Hex/SPION/Srfn) were constructed in this study for LPO produced to overcome the therapy-resistant state of cancer. Both in vitro and in vivo experiments were performed using breast cancer cells to investigate the anti-tumor efficacy of the complex self-assemblies.Results: The nano-device enriched the tumor sites by magnetic targeting of enhanced permeability and retention effects (EPR), which were disassembled by the redox response under high levels of ROS and GSH in FT cells. Superparamagnetic iron oxide nanoparticles (SPION) released Fe2+ and Fe3+ in the acidic environment of lysosomes, and the NIR photosensitizer Cy7-Hex anchored to the mitochondrial membrane, combined sorafenib (Srfn) leading to LPO burst, which was accumulated ~18-fold of treatment group in breast cancer cells. In vivo pharmacodynamic test results showed that this nanodevice with small particle size and high cytotoxicity increased Srfn circulation and shortened the period of epithelial cancer treatment.Conclusion: Ferroptosis therapy had a successful effect on EMT cells. These findings have great potential in the treatment of therapy-resistant epithelial cell carcinomas.
Utilizing
neutrophils (NEs) to target and deliver nanodrugs to
inflammation sites has received considerable attention. NEs are involved
in the formation and development of thrombosis by transforming into
neutrophil extracellular traps (NETs); this indicates that NEs may
be a natural thrombolytic drug delivery carrier. However, NEs lack
an effective power system to overcome blood flow resistance and enhance
targeting efficiency. Herein, we report the application of a urease
catalysis micromotor powered NEs nanodrug delivery system to promote
thrombolysis and suppress rethrombosis. The urease micromotor powered
Janus NEs (UM-NEs) were prepared by immobilizing the enzyme asymmetrically
onto the surface of natural NEs and then loading urokinase (UK) coupled
silver (Ag) nanoparticles (Ag-UK) to obtain the UM-NEs (Ag-UK) system.
Urease catalytic endogenous urea is used to generate thrust by producing
ammonia and carbon dioxide, which propels NEs actively targeting the
thrombus. The UM-NEs (Ag-UK) can be activated by enriched inflammatory
cytokines to release NETs at the thrombosis site, resulting in a concomitant
release of Ag-UK. Ag-UK induces thrombolysis to restore vascular recanalization.
This urease micromotor-driven NEs drug delivery system can significantly
reduce the hemorrhagic side effects, promote thrombolysis, and inhibit
rethrombosis with high bioavailability and biosafety, which can be
used for the treatment of thrombotic diseases.
Photodynamic therapy relies on photosensitizers to generate cytotoxic reactive oxygen species (ROS) resulting in the apoptois of tumor cells. However, there is an antioxidant system that impedes the elevation of oxidation levels in tumor cells. Thus, photodynamic therapy may exhibit insufficient curative effects due to ungenerous reactive oxygen species levels. Herein, we describe tumor-specific activated photodynamic therapy using an oxidation-regulating strategy.Methods: We first synthesised a reactive oxygen species-sensitive amphipathic prodrug of gambogic acid-grafted hyaluronic acid (HA-GA). The hydrophobic photosensitizer chlorin e6 (Ce6) was then loaded into HA-GA by hydrophobic interactions between GA and Ce6, forming amphipathic nanomicelles (HA-GA@Ce6). The ROS-responsive behavior, cytotoxicity, cell uptake, tumor cell killing, in vivo biodistribution and in vivo anti-tumor efficacy of HA-GA@Ce6 were investigated. The in vitro and in vivo experiments were performed on 4T1 murine breast cancer cells and 4T1 tumor model.Results: We validated that the micelles of HA-GA@Ce6 showed stronger cell uptake in 4T1 tumor cells and lower cytotoxicity in normal cells compared with free Ce6 and GA, which exhibited the benefits of nanomicelles on enhancing the tumor cell acumulation and reducing the side effects on normal cells synchronously. Additionally, the cytotoxic free radicals of photodynamic therapy were generated after irradiation and the high oxidation levels activated the ROS-sensitive GA prodrug efficiently, which killed the tumor cells and depleted intracellular glutathione (GSH), thereby impairing antioxidant levels and enhancing photodynamic therapy.Conclusion: With the successfully eradicated tumor growth in vivo. Our work represents a new photodynamic therapy concept, achieving superior anti-tumor efficacy by reducing intracellular antioxidant levels.
Ferroptosis
is an iron-dependent cell death caused by accumulation
of lipid peroxidation (LPO), which is a new strategy for cancer treatment.
Th current ferroptosis therapy nanodevices have low efficiency and
side effects generally. Hence, we developed a Black Hole Quencher
(BHQ)-based fluorescence “off–on” nanophotosensitizer
complex assembly (CSO-BHQ-IR780-Hex/MIONPs/Sor). CSO-connected BHQ-IR780-Hex
and -loaded magnetic iron oxide nanoparticles (MIONPs) and sorafenib
(Sor) formed a very concise functionalized delivery system. CSO-BHQ-IR780-Hex
disassembled by GSH attack and released IR780-Hex, MIONPs, and sorafenib.
IR780-Hex anchored to the mitochondrial membrane, which would contribute
to amplifying the efficiency of the photosensitizer. When NIR irradiation
was given to CSO-BHQ-IR780-Hex/MIONPs/Sor-treated cells, iron supply
increased, the xCT/GSH/GPX-4 system was triggered, and a lot of LPO
burst. A malondialdehyde test showed that LPO in complex assembly-treated
cells was explosive and increased about 18-fold compared to the control.
The accumulation process of particles was monitored by an IR780-Hex
photosensitizer, which showed an excellent tumor target ability by
magnetic of nanodevice in vivo. Interestingly, the half-life of sorafenib
in a nanodevice was increased about 26-fold compared to the control
group. Importantly, the complex assembly effectively inhibits tumor
growth in the breast tumor mouse model. This work would provide ideas
in designing nanomedicines for the ferroptosis treatment of cancer.
Scheme of mPEG-HA/CSO-SS-Hex/SPION/GA self-assembly preparation and the magnetism-enhanced EPR in vivo and in vitro trafficking pathways of the polymeric self-assembly.
The surgical removal of lesions is among the most common and effective treatments for atherosclerosis. It is often the only curative treatment option, and the ability to visualize the full extent of atherosclerotic plaque during the operation has major implications for the therapeutic outcome. Fluorescence imaging is a promising approach for the inspection of atherosclerotic plaques during surgery. However, there is no systematic strategy for intraoperative fluorescent imaging in atherosclerosis. In this study, the in situ attachment of a lipid‐activatable fluorescent probe (CN‐N2)‐soaked patch to the outer arterial surface is reported for rapid and precise localization of the atherosclerotic plaque in ApoE‐deficient mouse during surgery. Stable imaging of the plaque is conducted within 5 min via rapid recognition of abnormally accumulated lipid droplets (LDs) in foam cells. Furthermore, the plaque/normal ratio (P/N) is significantly enhanced to facilitate surgical delineation of carotid atherosclerotic plaques. Visible fluorescence bioimaging using lipid‐activatable probes can accurately delineate plaque sizes down to diameters of <0.5 mm, and the images can be swiftly captured within the stable plaque imaging time window. These findings on intraoperative fluorescent imaging of plaques via the in situ attachment of the CN‐N2 patch hold promise for effective clinical applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.